Influence of experimental rhinitis on the gonadotropin response to intranasal administration of buserelin

[1]  J. Klijn,et al.  LHRH-agonist treatment in clinical and experimental human breast cancer. , 1985, Journal of steroid biochemistry.

[2]  W. Uk,et al.  Long-term endocrine profiles of prostatic carcinoma patients under pernasal as well as intramuscular Gn-RH analogue treatment. , 1985 .

[3]  F. Schroeder,et al.  EORTC Genitourinary Group Monograph 2, Part A: Therapeutic principles in metastatic prostatic cancer. Proceedings of a symposium held in Rotterdam, The Netherlands, September 14 and 15, 1984. , 1985, Progress in clinical and biological research.

[4]  J. Sandow,et al.  A pharmaceutical approach to long-term therapy with peptides , 1984 .

[5]  N. Faure,et al.  Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (Buserelin) as a new therapeutic approach for endometriosis. , 1984, Fertility and sterility.

[6]  A. Luder,et al.  Intranasal and subcutaneous treatment of central precocious puberty in both sexes with a long-acting analog of luteinizing hormone-releasing hormone. , 1984, Journal of Clinical Endocrinology and Metabolism.

[7]  H. Fraser,et al.  Intranasal treatment with luteinising hormone releasing hormone agonist in women with endometriosis. , 1983, British medical journal.

[8]  N. Faure,et al.  Preliminary results on the clinical efficacy and safety of androgen inhibition by an LHRH agonist alone or combined with an antiandrogen in the treatment of prostatic carcinoma , 1983, The Prostate.

[9]  P. Osterhammel,et al.  Significance of H1 and H2 receptors in the human nose: rationale for topical use of combined antihistamine preparations. , 1982, The Journal of allergy and clinical immunology.

[10]  G Quesnel,et al.  Potential new treatment of endometriosis: reversible inhibition of pituitary-ovarian function by chronic intranasal administration of a luteinizing hormone-releasing hormone (LH-RH) agonist. , 1982, Fertility and sterility.

[11]  B. Jonson,et al.  Rhinomanometry. II. A system for numerical description of nasal airway resistance. , 1982, Acta oto-laryngologica.

[12]  J. Klijn,et al.  TREATMENT WITH A LUTEINISING-HORMONE-RELEASING-HORMONE ANALOGUE (BUSERELIN) IN PREMENOPAUSAL PATIENTS WITH METASTATIC BREAST CANCER , 1982, The Lancet.

[13]  M. Schmidt-gollwitzer,et al.  SUSTAINED SUPPRESSION OF TESTOSTERONE PRODUCTION BY THE LUTEINISING-HORMONE RELEASING-HORMONE AGONIST BUSERELIN IN PATIENTS WITH ADVANCED PROSTATE CARCINOMA A New Therapeutic Approach? , 1982, The Lancet.

[14]  A Ivarsson,et al.  Rhinomanometry. I. Simple equipment. , 1982, Acta oto-laryngologica.

[15]  D Ackman,et al.  Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[16]  M. Schmidt-gollwitzer,et al.  Influence of the LH-RH analogue buserelin on cyclic ovarian function and on endometrium. A new approach to fertility control? , 1981, Contraception.

[17]  J. Sandow,et al.  Pharmacology of LH-RH and its analogues. , 1981 .

[18]  P. Crosignani,et al.  Endocrinology of human infertility : new aspects , 1981 .

[19]  C. Bergquist,et al.  Inhibition of ovulation in women by chronic treatment with a stimulatory LRH analogue--a new approach to birth control? , 1978, Contraception.